DO INDONESIAN GOVERNMENT DEPLOY RELIABLE AMMUNITION FOR COVID-19 MASS TEST? A COMPARISON OF REAL-TIME PCR KITS

NELLY MARISSA; SALMIATY; SARI HANUM; EVAN FEBRIANSYAH; NUR RAMADHAN; YULIDAR; ZAIN HADIFAH; AGUNG PRANATA

doi:10.22159/ajpcr.2021.v14i5.40078

Authors

NELLY MARISSA Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh, Indonesia.
SALMIATY Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh, Indonesia.
SARI HANUM Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh, Indonesia.
EVAN FEBRIANSYAH Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh, Indonesia.
NUR RAMADHAN Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh, Indonesia.
YULIDAR Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh, Indonesia.
ZAIN HADIFAH Balai Penelitian dan Pengembangan Kesehatan Aceh, Aceh, Indonesia.
AGUNG PRANATA Department of Parasitology, School of Medicine, Universitas Syiah Kuala, Aceh, Indonesia.

DOI:

https://doi.org/10.22159/ajpcr.2021.v14i5.40078

Keywords:

SARS-CoV-2, COVID 19, PCR

Abstract

Objective: This study aimed to compare the level of reliability of three commercial real-time PCR kits in determining clinical samples.

Methods: A total of 40 swabs samples which were previously tested positive, were re-test using the BioCov-19 RT-PCR kit, Sansure coronavirus disease 19 (COVID-19) nucleic acid diagnostic kit, and Kogen PowerCheck with Thermocycler (Roche). The amplification procedure is carried out based on the manual for each kit.

Results: Sansure COVID-19 nucleic acid diagnostic was able to detect 40 samples with positive severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) results detected in both genes, while the PowerChek™ 2019-nCoV real-time PCR kit able to detect 35 samples showed that SARS-COV-II was detected in both genes, and the BioCoV-19 RT-PCR Kit brand kit able to detect 34 samples showed positive SARS-COV-2 results in both genes.

Conclusion: The three commercial kits show great ability detection, so that they can be used to detect the presence of SARS-COV-II in clinical samples, and also in mass screening.

Downloads

Download data is not yet available.

References

Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020;9:221-36.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020;395:565-74.

Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep 2020;19:100682.

Mollaei HR, Afshar AA, Kalantar-Neyestanaki D, Fazlalipour M, Aflatoonian B. Comparison five primer sets from different genome region of covid-1for detection of virus infection by conventional rt-pcr. Iran J Microbiol 2020;12:185-93.

Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25:2000045.

Iglói Z, leven M, Abou-Nouar ZA, Weller B, Matheeussen V, Coppens J, et al. Comparison of commercial realtime reverse transcription PCR assays for the detection of SARS-CoV-2. J Clin Virol 2020;129:104510.

van Kasteren PB, van der Veer B, van den Brink S, Wijsman L, De Jonge J, van den Brandt A, et al. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. J Clin Virol 2020;128:104412.